Form 4: Ultragenyx CFO Horn Reports Stock Transactions

Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, reported the acquisition of shares from performance units and subsequent sales for tax obligations and other purposes.

Summary

• Howard Horn, Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (RARE), reported multiple transactions involving the company's common stock.
• On March 1, 2026, Horn acquired 6,143 shares of common stock at a price of $0. These shares resulted from the conversion of previously granted performance stock units upon the certification of performance metrics.
• On March 2, 2026, Horn sold 5,290 shares of common stock at a weighted average price of $22.8 per share. These shares were sold to cover required tax withholdings due to the vesting of Restricted Stock Units (RSUs).
• Also on March 2, 2026, an additional 3,119 shares of common stock were sold at a price of $22.54 per share.
• On March 3, 2026, 1,635 shares of common stock were sold at a price of $22.4 per share.
• Following these reported transactions, Horn's direct beneficial ownership of common stock stands at 85,034 shares, which includes shares underlying RSUs subject to certain vesting conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. The acquisition of shares from performance units is positive, indicating goal achievement, while the sales are largely routine for tax purposes, though some additional sales occurred.

Positives

• The acquisition of 6,143 shares on March 1, 2026, indicates that performance metrics for previously granted performance stock units were successfully met and certified.

Negatives

• A total of 10,044 shares were disposed of between March 2 and March 3, 2026, reducing the direct beneficial ownership of the Chief Financial Officer.

Future Outlook

This filing, a Form 4, reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider transaction filings like Form 4 provide transparency into executive stock movements. While the sale of shares for tax obligations is a routine event following RSU vesting, the achievement of performance metrics leading to share acquisition can be viewed positively, indicating internal goal attainment. These transactions are common in the biotechnology sector where executive compensation often includes equity awards.

Stakeholder Impact

• Shareholders may observe the Chief Financial Officer's stock movements, which include both the receipt of performance-based equity and subsequent sales, primarily for tax purposes.

Key Dates

Recommendation

The filing details routine insider transactions, including the vesting of performance-based awards and subsequent sales, primarily for tax obligations. While the achievement of performance metrics leading to share acquisition is positive, the net reduction in direct beneficial ownership does not provide a strong signal for a change in investment stance. Therefore, a 'hold' recommendation is appropriate as this filing alone does not present new fundamental information to alter the company's investment thesis.

Keywords

Ultragenyx, RARE, Howard Horn, CFO, Insider Transaction, Form 4, Performance Stock Units, RSU Vesting, Share Sale, Tax Withholding